Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: SRPT stock price vs NLY: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at NLY's multiple
Needs NLY P/S.
Implied fair value · at SRPT's multiple
Needs Revenue / share, SRPT P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Higher is better
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: SRPT FY 2025 (ended Dec 31, 2025) · NLY FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
SAREPTA THERAPEUTICS, INC. · implied price per share
Bear
-$43.23
Base
-$50.86
Bull
-$58.48
ANNALY CAPITAL MANAGEMENT INC · implied price per share
Bear
$452.39
Base
$532.22
Bull
$612.05
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.82x
0.03x
Net debt / EBITDA
Leverage against operating earnings
0.01x
-0.12x
Cash and equivalents
Liquid reserves on the balance sheet
$939.65M
$1.41B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
SRPT vs AMGN
BIOMARIN PHARMACEUTICAL INC
SRPT vs BMRN
Replimune Group, Inc.
SRPT vs REPL
PTC THERAPEUTICS, INC.
SRPT vs PTCT
AGNC Investment Corp.
SRPT vs AGNC
TWO HARBORS INVESTMENT CORP.
SRPT vs TWO
Armour Residential REIT, Inc.
SRPT vs ARR
STARWOOD PROPERTY TRUST, INC.
SRPT vs STWD
DYNEX CAPITAL INC
SRPT vs DX
$934.46M
$429.65M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe SRPT can materially improve margins and turn positive free cash flow despite its current -32.5% net margin and 2/9 Piotroski score, then the stock may be worth holding or buying near the lower end of its historical range because the current 0.9x P/S multiple already discounts weak execution.
SRPT trades at 0.9x EV/Revenue and 0.9x P/S, which is low in absolute terms, but the discount is not supported by earnings quality or margins. The stock is also below the midpoint of its historical band at $19.28 versus a $17.35-$21.21 range, suggesting it is not obviously mispriced to the upside on the data provided.
Supporting Metrics
